CD24 and neoplasm: Genetic deletion and therapeutic inhibition of either CD24 or Siglec-10, as well as blocking their interaction using mAbs, can augment the phagocytic capacity of macrophages in CD24-expressing human tumours and promotes tumour-specific responses [225, 227].